Picard Medical Disclosed Failure to Satisfy a Continued Listing Rule or Standard

On July 22, 2026, NYSE American accepted the company's plan to regain compliance with Sections 1003(a)(i) and (ii) after reporting low stockholders' equity/deficit and losses in three of four recent fiscal years. Picard Medical will remain listed subject to meeting plan milestones, quarterly review, and has up to 18 months from the original notice to regain compliance.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.